

REFERENCES

1. NIAID [Internet]. NIAID Fact Sheet: HIV/AIDS Statistics. Available from: www.niaid.nih.gov/factsheets/aidsstat.htm.
2. Koblin BA et al. High-risk behavior among men who have sex with men in 6 US cities: baseline data from the EXPLORE study. *Am J Public Health* 2003;93:926-932.
3. Chesney MA et al. An individually tailored intervention for HIV prevention: baseline data from the EXPLORE study. *Am J Public Health* 2003;93:933-938.
4. Miller KD et al. Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion. *J Clin Immunol* 2001;99:30-42.
5. Dybul M et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus effects on drug toxicity and on immunologic and virologic parameters. *J Infect Dis* 2003;188:388-396.
6. WHO. *Wkly Epidemiol Rec* 1999;32:265-272. Available from: www.who.int/wer.
7. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002. *Am J Infect Control* 2002;30:458-475.
8. WHO Division of Control of Tropical Diseases, *Malaria control—burden and trends*.
9. Espinal MA et al. Global trends in resistance to antituberculosis drugs. *N England J Med* 2001; 344:1294-1303.
10. Taylor DN. The growing problem of antimicrobial resistance among enteric pathogens. *Clin Updates Infect Dis* 2003;6:1-3.
11. Parry CM. Antimicrobial drug resistance in *Salmonella enterica*. *Curr Opin Infect Dis* 2003;16:467-472.
12. Tjaniadi P et al. Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia. *Am J Trop Med Hyg* 2003;68:666-670.
13. Boshoff HIM et al. DnaE2 polymerase contributes to *in vivo* survival and the emergence of drug resistance in *Mycobacterium tuberculosis*. *Cell* 2003;113:183-193.
14. Matricardi PM et al. Hay fever and asthma in relation to markers of infection in the United States. *J Allergy Clin Immunol* 2002;110:381-387.
15. Beasley R et al. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *Lancet* 1998;351:1225-1232.
16. Linneberg A et al. The prevalence of skin-test-positive allergic rhinitis in Danish adults: two cross-sectional surveys 8 years apart. The Copenhagen Allergy Study. *Allergy* 2000;55:767-772.
17. CDC. Series 10, No. 205. Table 4. Percents (with standard errors) of selected respiratory diseases among persons 18 years of age and over, by selected characteristics: United States, 1997. www.cdc.gov/nchs/fastats/pdf/sr10_205t4.pdf.
18. Beasley R et al., 1998.
19. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of allergy, allergic rhino conjunctivitis, and atopic eczema. *Lancet* 1998;351:1225-32.
20. *Immunology Clinics NA* 2002;22:1-25.
21. Matsumoto I et al. Change in prevalence of allergic diseases in primary school children in Fukuoka City for the last fifteen years. *Arerugi* 1999;(48):435-442.
22. *Br J Dermatol* 2000;143:992-998.
25. Sampson HA. Peanut allergy. *N Engl J Med* 2002;346:1294-1299.
26. Sicherer SH. Food allergy. *Lancet* 2002;360:701-710.
27. Sicherer SH et al. Prevalence of peanut and tree nut allergy in the US determined by a random digit dial telephone survey. *J Allergy Clin Immunol* 1999; 103:559-562.
28. AAAAI. Anaphylaxis in schools and other child-care settings. Position statement #34. *J Allergy Clin Immunol* 1998;102:173-176.

27. Yocum MW, Khan DA. Assessment of patients who have experienced anaphylaxis: a 3-year survey. *Mayo Clin Proc* 1994; 69(1):16-23.
28. Pumphrey RS, Stanworth SJ. The clinical spectrum of anaphylaxis in north-west England. *Clin Exp Allergy* 1996;26(12):1364-1370.
29. Centers for Disease Control and Prevention [Internet]. City, State: National Center for Health Statistics; January 28, 2003. Asthma prevalence, healthcare use and mortality, 2000-2001. Available from: www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm.
30. Akimbami LJ, Schoendorf KC. Trends in childhood asthma: prevalence, healthcare utilization, and mortality. *Pediatrics* 2002;110(2):315-322.
31. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. *J Allergy Clin Immunol* 2001;107(1):3-8.
32. Moayeri M et al. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. *J Clin Invest* 2003;112:670-682.
33. Kobayashi SD et al. Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. *Proc Natl Acad Sci USA* 2003; 100:10948-10953.
34. Earl P et al. Vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein: development and use. *J Viro*, in press.
35. Kocisko DA et al. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. *J Virol* 2003; 77:10288-10294.
36. Dye C et al. Global burden of tuberculosis. *JAMA* 1999;282:677-686.
37. UNAIDS/WHO. AIDS epidemic update, December 2001. Available from: www.unaids.org/epidemic_update/report_dec01/index.html#full.
38. Amara RR et al. *Science* 2001;292:69-74.
39. Addo M et al. *Proc Natl Acad Sci USA* 2001;98:1781-1786.
40. Evans T et al. Abstract WeOrC559, XIII International AIDS Conference, 2000.
41. Durbin AP et al. Attenuation and immunogenicity in humans of a live dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. *Am J Trop Med Hyg* 2001;65:405-413.
42. Chen H et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. *Vaccine* 2003, in press.
43. Malaria at a glance factsheet, World Bank, March 2001. Available from: www1.worldbank.org/hnp/Malaria/Malaria_publications.asp.
44. NIAID/NIH. Blueprint for tuberculosis vaccine development. Report of a workshop held March 5-6, 1998. *Clin Infect Dis* 2000;30 Suppl 3.
45. Centers for Disease Control and Prevention [Internet]. Reported tuberculosis in the United States (selected tables), 2001. Available from: www.cdc.gov/nchstp/tb.
46. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. *Sex Transm Dis* 1999;26(4 suppl):S2-7.
47. Jackson JB et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 month follow-up of the HIVNET 012 randomized trial. *Lancet* 2003;362(9387):859-868.
48. CDC. *Tracking the hidden epidemics: trends in STDs in the United States*, 2000. www.cdc.gov/nchstp/dstd/stats_trends2000.pdf.
49. Organ Procurement and Transplantation Network Data. Available from: www.optn.org/data/. Accessed September 5, 2003.
50. Ibid.
51. WHO. *Tuberculosis fact sheet* (1995-2005).
52. Karron R et al. A live human parainfluenza type 3 vaccine is attenuated and immunogenic in young infants. *Pediatr Infect Dis J* 2003;22(5):394-405.

53. Bukreyev A et al. More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved? *Proc Natl Acad Sci USA* 2002;99:16987-16991.
54. Shapiro AM et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N Engl J Med* 2000;343(4):230-238.
55. Stowers AW et al. Vaccination of monkeys with recombinant *Plasmodium falciparum* apical membrane antigen 1 confers protection against blood-stage malaria. *Infect Imm* 2002;70:6961-6967.
56. Whitehead SS et al. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. *Vaccine* 2003;21:4307-4316.